DE69132299D1 - Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs - Google Patents
Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von KrebsInfo
- Publication number
- DE69132299D1 DE69132299D1 DE69132299T DE69132299T DE69132299D1 DE 69132299 D1 DE69132299 D1 DE 69132299D1 DE 69132299 T DE69132299 T DE 69132299T DE 69132299 T DE69132299 T DE 69132299T DE 69132299 D1 DE69132299 D1 DE 69132299D1
- Authority
- DE
- Germany
- Prior art keywords
- alpha
- antisense oligonucleotides
- camp
- cancer
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title abstract 3
- 238000012230 antisense oligonucleotides Methods 0.000 title abstract 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 title 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60711390A | 1990-11-02 | 1990-11-02 | |
US68019891A | 1991-04-05 | 1991-04-05 | |
US07/702,163 US5271941A (en) | 1990-11-02 | 1991-05-20 | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69132299D1 true DE69132299D1 (de) | 2000-08-10 |
DE69132299T2 DE69132299T2 (de) | 2001-02-15 |
Family
ID=27416969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69132299T Expired - Fee Related DE69132299T2 (de) | 1990-11-02 | 1991-10-31 | Antisense Oligonukleotide gegen die alpha-regulatorische Untereinheit der cAMP-abhängigen Protein-Kinase zur Behandlung von Krebs |
DE69127175T Expired - Fee Related DE69127175T2 (de) | 1990-11-02 | 1991-10-31 | Antisens-Oligonukleotide zur Behandlung von Krebs |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69127175T Expired - Fee Related DE69127175T2 (de) | 1990-11-02 | 1991-10-31 | Antisens-Oligonukleotide zur Behandlung von Krebs |
Country Status (9)
Country | Link |
---|---|
US (3) | US5271941A (de) |
EP (3) | EP0972831A1 (de) |
KR (1) | KR0171210B1 (de) |
AT (2) | ATE194383T1 (de) |
CA (2) | CA2054325C (de) |
DE (2) | DE69132299T2 (de) |
DK (2) | DK0785252T3 (de) |
ES (2) | ES2148838T3 (de) |
GR (2) | GR3024673T3 (de) |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
US5646267A (en) * | 1991-08-05 | 1997-07-08 | Polish Academy Of Sciences | Method of making oligonucleotides and oligonucleotide analogs using phospholanes and enantiomerically resolved phospholane analogues |
US5359052A (en) * | 1991-08-05 | 1994-10-25 | Polish Academy Of Sciences | Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates |
US6995146B2 (en) * | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
CA2158347A1 (en) | 1993-03-26 | 1994-10-13 | Renato Baserga | Method of inhibiting the proliferation and causing the differentiation of cells with igf-1 receptor antisense oligonucleotides |
US6340674B1 (en) | 1993-03-26 | 2002-01-22 | Thomas Jefferson University | Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides |
US5639872A (en) * | 1993-07-27 | 1997-06-17 | Hybridon, Inc. | Human VEGF-specific oligonucleotides |
PT1584682E (pt) * | 1993-09-20 | 2009-08-03 | Univ Pennsylvania | Regulação da expressão do gene bcl-2 |
US5618709A (en) * | 1994-01-14 | 1997-04-08 | University Of Pennsylvania | Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein |
US5726297A (en) * | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US6608035B1 (en) * | 1994-10-25 | 2003-08-19 | Hybridon, Inc. | Method of down-regulating gene expression |
US6645943B1 (en) | 1994-10-25 | 2003-11-11 | Hybridon, Inc. | Method of down-regulating gene expression |
US5969117A (en) * | 1995-08-17 | 1999-10-19 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotide |
US7074768B2 (en) * | 1995-08-17 | 2006-07-11 | Idera Pharmaceuticals, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US20050054600A1 (en) * | 1995-08-17 | 2005-03-10 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotides and methods of their use |
US6624293B1 (en) * | 1995-08-17 | 2003-09-23 | Hybridon, Inc. | Modified protein kinase A-specific oligonucleotides and methods of their use |
US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
US6180767B1 (en) | 1996-01-11 | 2001-01-30 | Thomas Jefferson University | Peptide nucleic acid conjugates |
US6977244B2 (en) * | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
EP1007656B1 (de) * | 1997-03-12 | 2006-09-13 | Idera Pharmaceuticals, Inc. | Verändertes protein kinase a-spezifisches hybrid oligonukleotid in kombination mit paclitaxol und verfahren ihrer anwendung |
US7285288B1 (en) | 1997-10-03 | 2007-10-23 | Board Of Regents, The University Of Texas System | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
US7704962B1 (en) | 1997-10-03 | 2010-04-27 | Board Of Regents, The University Of Texas System | Small oligonucleotides with anti-tumor activity |
US6312941B1 (en) | 1997-11-26 | 2001-11-06 | The Regents Of The University Of Michigan | Compositions and methods for identifying signaling pathway agonists and antagonists |
AU5618700A (en) * | 1999-06-18 | 2001-01-09 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
US6489356B2 (en) | 2000-09-05 | 2002-12-03 | Edward Leung | Method for treating pain in humans |
EP2351855A1 (de) | 2000-09-26 | 2011-08-03 | Duke University | RNA-Aptamere und Verfahren zu ihrer Identifizierung |
AU2001296846B2 (en) | 2000-10-12 | 2007-07-05 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
KR100408916B1 (ko) * | 2000-11-23 | 2003-12-11 | 주식회사 바이오제니아 | 마이코락톤을 함유하는 항암제, 사람 레티노블라스토마단백질의 발현을 저하시키는 안티센스 올리고누클레오티드및 마이코락톤과 상기 안티센스 올리고누클레오티드를함유하는 항암제 |
US6524854B1 (en) * | 2001-09-11 | 2003-02-25 | Isis Pharmaceuticals, Inc. | Antisense inhibition of PKA regulatory subunit RII alpha expression |
DE60332756D1 (de) | 2002-02-06 | 2010-07-08 | Vicor Technologies Inc | Anti-infarkt-moleküle |
WO2003093452A2 (en) * | 2002-02-26 | 2003-11-13 | University Of Utah Research Foundation | Variants of nedd4l associated with hypertension and viral budding |
CA2495478A1 (en) | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
WO2004053073A2 (en) * | 2002-12-05 | 2004-06-24 | The Research Foundation Of State University Of Newyork | HIGH EFFICACY ANTISENSE Riα PKA POLY-DNP OLIGORIBONUCLEOTIDES |
US20050069918A1 (en) * | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
EP1744761A4 (de) * | 2004-04-28 | 2010-01-13 | Molecules For Health Inc | Verfahren zur behandlung oder prävention von restenose und anderen proliferativen gefässstörungen |
WO2005112978A2 (en) | 2004-05-21 | 2005-12-01 | University Of Utah Research Foundation | Methods and compositions related to delivery of chemical compounds to invertebrate embryos |
EP2484780A1 (de) | 2004-07-23 | 2012-08-08 | The University of North Carolina At Chapel Hill | Verfahren und Materialien zur Bestimmung der Schmerzempfindlichkeit und Vorhersage und Behandlung zugehöriger Störungen |
EP2551282A3 (de) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antikörper gegen CD38 zur Behandling von multiplem Myelom |
US8703769B2 (en) * | 2005-07-15 | 2014-04-22 | The University Of North Carolina At Chapel Hill | Use of EGFR inhibitors to prevent or treat obesity |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
EP1934331A4 (de) | 2005-10-14 | 2009-01-21 | Musc Found For Res Dev | Pax2 als ziel für die induktion von defb1-vermittelter tumorimmunität und krebstherapie |
LT2056845T (lt) | 2006-08-08 | 2017-11-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5` fosfato oligonukleotidų struktūra ir panaudojimas |
AU2007297535C1 (en) | 2006-09-21 | 2017-11-23 | University Of Florida Research Foundation, Inc. | Compositions and methods related to protein displacement therapy for myotonic distrophy |
WO2008136852A2 (en) | 2006-11-01 | 2008-11-13 | University Of Rochester | Methods and compositions related to the structure and function of apobec3g |
CA2672297A1 (en) | 2006-12-11 | 2008-06-19 | University Of Utah Research Foundation | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
EP2030615A3 (de) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonukleotidreduktase-Inhibitoren zur Verwendung für die Behandlung oder Vorbeugung von Nervenentzündung- oder Autoimmunerkrankungen |
JP2010537638A (ja) | 2007-08-28 | 2010-12-09 | ユーエービー リサーチ ファウンデーション | 合成アポリポ蛋白質e模倣ポリペプチドおよび使用方法 |
DK2682400T5 (da) | 2007-08-28 | 2017-11-27 | Uab Research Foundation | Syntetiske apolipoprotein E-efterlignende polypeptider og fremgangsmåder til anvendelse |
US7828840B2 (en) * | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
CA2706317C (en) | 2007-12-03 | 2017-06-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Doc1 compositions and methods for treating cancer |
EP2288922B1 (de) | 2008-05-08 | 2016-08-17 | University of Utah Research Foundation | Sensorische rezeptoren für chronische müdigkeit und schmerzen und verwendungen dafür |
EP2297323A1 (de) | 2008-05-21 | 2011-03-23 | Hartmann, Gunther | 5 -triphosphat-oligonukleotid mit stumpfem ende und verwendugen davon |
WO2010027641A2 (en) * | 2008-08-15 | 2010-03-11 | Georgetown University | Na channels, disease, and related assays and compositions |
EP2370080A1 (de) | 2008-12-02 | 2011-10-05 | University of Utah Research Foundation | Pde1 als zieltherapeutikum bei herzkrankheiten |
US20110060000A1 (en) | 2009-09-10 | 2011-03-10 | Maurizio Grimaldi | Acridine analogs in the treatment of gliomas |
US20110207789A1 (en) | 2010-02-19 | 2011-08-25 | Ye Fang | Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents |
DK2580243T3 (da) | 2010-06-09 | 2020-01-13 | Genmab As | Antibodies against human cd38 |
EP2508530A1 (de) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags |
EP2712870A1 (de) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Neuartige RIG-I-Liganden und Herstellungsverfahren dafür |
US9970002B2 (en) | 2012-12-12 | 2018-05-15 | Massachusetts Institute Of Technology | Compositions and methods for functional nucleic acid delivery |
EP3071590A4 (de) | 2013-11-21 | 2017-07-19 | SeNA Research, Inc. | Verfahren zur strukturbestimmung von selenderivatisierten nukleinsäurekomplexen |
BR112017001860A2 (pt) | 2014-07-31 | 2018-02-27 | Uab Research Foundation | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal |
ES2893114T3 (es) | 2015-02-04 | 2022-02-08 | Bristol Myers Squibb Co | Métodos para seleccionar moléculas terapéuticas |
MX2017010066A (es) | 2015-02-04 | 2017-11-01 | Hoffmann La Roche | Oligomeros antisentido de tau y usos de los mismos. |
WO2018022967A1 (en) | 2016-07-28 | 2018-02-01 | Regeneron Pharmaceuticals, Inc. | Gpr156 variants and uses thereof |
US11123435B2 (en) | 2016-08-03 | 2021-09-21 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | TLR9 targeted therapeutics |
BR112019014841A2 (pt) | 2017-01-23 | 2020-04-28 | Regeneron Pharma | rna guia, uso do rna guia, rna antissentido, sirna ou shrna, uso do rna antissentido, do sirna ou do shrna, ácido nucleico isolado, vetor, composição, célula, e, métodos para modificar um gene hsd17b13 em uma célula, para diminuir a expressão de um gene hsd17b13 em uma célula, para modificar uma célula e para tratar um indivíduo que não é portador da variante de hsd17b13 |
AU2018282072A1 (en) | 2017-06-05 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | B4GALT1 variants and uses thereof |
IL272940B1 (en) | 2017-09-06 | 2024-02-01 | Regeneron Pharma | Variants linked to the interleukin-1 immunoglobulin-single receptor and their uses |
AU2018330458A1 (en) | 2017-09-07 | 2020-03-19 | Regeneron Pharmaceuticals, Inc. | Solute Carrier Family 14 Member 1 (SLC14A1) variants and uses thereof |
CA3078883A1 (en) | 2017-10-11 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | Inhibition of hsd17b13 in the treatment of liver disease in patients expressing the pnpla3 i148m variation |
JP2021501601A (ja) | 2017-10-16 | 2021-01-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | コルヌリン(crnn)バリアント及びその使用 |
MA56457A (fr) | 2019-07-02 | 2022-05-11 | Regeneron Pharma | Modulateurs de hsd17b13 et leurs procédés d'utilisation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
NO864301L (no) * | 1986-10-28 | 1988-04-29 | Tore Jahnsen | Dna-prober for human regulatorisk enhet av camp-avhengige proteinkinaser. |
AU4180889A (en) * | 1988-07-05 | 1990-02-05 | Baylor College Of Medicine | Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria |
US5098890A (en) * | 1988-11-07 | 1992-03-24 | Temple University-Of The Commonwealth System Of Higher Education | Antisence oligonucleotides to c-myb proto-oncogene and uses thereof |
US5087617A (en) * | 1989-02-15 | 1992-02-11 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of cancer using oligonucleotides |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
-
1991
- 1991-05-20 US US07/702,163 patent/US5271941A/en not_active Expired - Lifetime
- 1991-10-28 CA CA002054325A patent/CA2054325C/en not_active Expired - Fee Related
- 1991-10-28 CA CA002488792A patent/CA2488792A1/en not_active Abandoned
- 1991-10-31 ES ES97100277T patent/ES2148838T3/es not_active Expired - Lifetime
- 1991-10-31 ES ES91118628T patent/ES2104644T3/es not_active Expired - Lifetime
- 1991-10-31 AT AT97100277T patent/ATE194383T1/de not_active IP Right Cessation
- 1991-10-31 EP EP99119780A patent/EP0972831A1/de not_active Withdrawn
- 1991-10-31 EP EP91118628A patent/EP0490077B1/de not_active Expired - Lifetime
- 1991-10-31 AT AT91118628T patent/ATE156517T1/de not_active IP Right Cessation
- 1991-10-31 DK DK97100277T patent/DK0785252T3/da active
- 1991-10-31 DE DE69132299T patent/DE69132299T2/de not_active Expired - Fee Related
- 1991-10-31 DE DE69127175T patent/DE69127175T2/de not_active Expired - Fee Related
- 1991-10-31 DK DK91118628.6T patent/DK0490077T3/da active
- 1991-10-31 EP EP97100277A patent/EP0785252B1/de not_active Expired - Lifetime
- 1991-11-02 KR KR1019910019468A patent/KR0171210B1/ko not_active IP Right Cessation
-
1993
- 1993-05-14 US US08/060,984 patent/US5627158A/en not_active Expired - Fee Related
-
1995
- 1995-02-02 US US08/383,742 patent/US5691317A/en not_active Expired - Fee Related
-
1997
- 1997-09-10 GR GR970402319T patent/GR3024673T3/el unknown
-
2000
- 2000-10-02 GR GR20000402225T patent/GR3034535T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0490077A1 (de) | 1992-06-17 |
EP0972831A1 (de) | 2000-01-19 |
DK0490077T3 (da) | 1998-01-26 |
KR0171210B1 (ko) | 1999-02-01 |
EP0785252B1 (de) | 2000-07-05 |
ATE156517T1 (de) | 1997-08-15 |
CA2054325C (en) | 2005-03-15 |
DE69127175T2 (de) | 1998-03-12 |
ES2104644T3 (es) | 1997-10-16 |
DE69127175D1 (de) | 1997-09-11 |
CA2054325A1 (en) | 1992-05-03 |
US5627158A (en) | 1997-05-06 |
EP0785252A1 (de) | 1997-07-23 |
GR3034535T3 (en) | 2001-01-31 |
CA2488792A1 (en) | 1992-05-03 |
GR3024673T3 (en) | 1997-12-31 |
DE69132299T2 (de) | 2001-02-15 |
ATE194383T1 (de) | 2000-07-15 |
EP0490077B1 (de) | 1997-08-06 |
DK0785252T3 (da) | 2000-10-02 |
US5691317A (en) | 1997-11-25 |
US5271941A (en) | 1993-12-21 |
ES2148838T3 (es) | 2000-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE194383T1 (de) | Antisense oligonukleotide gegen die alpha- regulatorische untereinheit der camp-abhängigen protein-kinase zur behandlung von krebs | |
ES2160707T3 (es) | Composiciones que comprenden agentes deteriorantes del adn y p53. | |
BG104599A (en) | Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas | |
DE69310634D1 (de) | Verwendung von Taxol zur Herstellung eines Arzneimittels zur Behandlung von Krebs | |
PT1019040E (pt) | Inibicao da actividade de p38-quinase por meio de arilureias | |
BR9814857A (pt) | Processos para tratar leucemia, câncer sólido eleucemia, linfoma ou tumores sólidos em umhumano, e para fabricar uma composiçãofarmacêutica estéril, e, a respectiva composiçãofarmacêutica estéril | |
MD960330A (ro) | Compuşi nepeptidilici, compoziţie farmaceutică pe baza acestora, metodă de tratament | |
DE69230046D1 (de) | 2-Bromomelatonin zur Behandlung von Schlafstörungen | |
DE69432315D1 (de) | ANTISENSE NUKLEINSÄUREN ZUR VORBEUGUNG UND BEHANDLUNG VON BESCHWERDEN IN WELCHEN DIE EXPRIMIERUNG VON C-erbB-2 EINE ROLLE SPIELT | |
DE69533112D1 (de) | Verwendung von flavolignanen zur herstellung von medikamenten mit antiproliferativer aktivität in gebärmutter,brust,eierstöcken | |
DE69906671D1 (de) | Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen | |
BR9813318A (pt) | Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário | |
DE69429806D1 (de) | Pharmazeutische zusammensetzungen zur prävention und behandlung von krebserkrankungen und verfahren für ihre herstellung | |
DE69924304D1 (de) | N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin | |
EP0281070A3 (de) | Pharmazeutische Zusammensetzung für die Krebsbehandlung | |
DE3887068D1 (de) | 2,2-Dimethylchromenderivate, Verfahren zur Herstellung und diese enthaltende pharmazeutische Zusammenstellungen. | |
DE69334087D1 (de) | Arzneimittelzusammensetzung enthaltend TCF-II | |
DE3687233T2 (de) | Pharmazeutische zusammensetzungen zur behandlung von hautkrankheiten. | |
ATE22282T1 (de) | Pentacycloundecan derivate, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen. | |
ATE247965T1 (de) | Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung | |
ATE194911T1 (de) | Anwendung von selegilin in tiermedizin | |
KR900017599A (ko) | 종양 치료용 약학 조성물 | |
SE8802323D0 (sv) | 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it | |
DE3782661T2 (de) | Pharmazeutische zusammensetzungen zur behandlung von krebs. | |
RU93019942A (ru) | Гомеопатический состав для лечения энтереколита человека и теплокровных животных |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |